Document is current

Article History

Received: 17 March 2021

Accepted: 13 April 2021

First Online: 4 May 2021

Change Date: 29 October 2021

Change Type: Update

Change Details: The funding note was missing in the original publication. The article has been updated to rectify the error.

Declarations

:

: EDGI was approved by 1) the University of North Carolina Biomedical Institutional Review Board (IRB) Protocol # 19–1387; 2) QIMR Berghofer Human Research Ethics Committee (QIMRB-HREC approval P3550).; 3) New Zealand Health and Disability Ethics Committees 20/CEN/1; and 4) Danish Scientific Ethics Committee, the Danish Health Data Authority, the Danish data protection agency and the Danish Neonatal Screening Biobank Steering Committee. All participants in the US, AU, and NZ provided informed online consent to participate. The electronic consent process was approved by the ethical committees.

: Not applicable.

: C.M. Bulik: Shire (grant recipient, Scientific Advisory Board member); Idorsia (consultant); Pearson (author, royalty recipient).L.M. Thornton: no competing interests to declare.R. Parker: no competing interests to declare.H. Kennedy: no competing interests to declare.C. MacDermod: no competing interests to declare.J. Guintivano: no competing interests to declare.L. Cleland: no competing interests to declare.A.L. Miller: no competing interests to declare.L.E. Harper: no competing interests to declare.J.T. Larsen: no competing interests to declare.Z. Yilmaz: no competing interests to declare.J. Grove: no competing interests to declare.P.F. Sullivan reports: Lundbeck (advisory committee, grant recipient), RBNC Therapeutics (advisory committee, shareholder).L.V. Petersen: no competing interests to declare.J. Jordan: no competing interests to declare.M. Kennedy: no competing interests to declare.N.G. Martin: no competing interests to declare.